Allergic Conjunctivitis

As long as I’m on the topic I got to thinking, do we really need another topical antihistamine drop? It’s a good time to ask because the rabble rousers at Eyevance have kicked their disruptive business model into high gear with the announcement of the Zerviate launch. As an aside, their answer to “do we need another topical steroid drop?” is the return of Tobradex ST.

The first patient has been enrolled in a phase 3 trial of Aldeyra Therapeutics’ allergic conjunctivitis treatment candidate reproxalap, according to a press release.

Topical ocular reproxalap improved ocular dryness more than vehicle in the first part of a phase 3 trial, Aldeyra Therapeutics announced in a press release.

The Canadian Drug Expert Committee has issued a reimbursement recommendation for Verkazia eye drops, a treatment for severe vernal keratoconjunctivitis, according to a press release.

by Mitch Ibach, OD , FAAO

Ocular Therapeutix will restructure its operations, resulting in approximately $11 million in annualized savings, according to a press release.

Aldeyra Therapeutics will initiate the phase 3 INVIGORATE trial of topical ocular reproxalap following positive results from an allergen chamber clinical methods trial, according to a press release.

Whether you are speaking at or listening to a CME lecture or a sponsored dinner program, the number of dry eye disease patients in the U.S. is given as either 16 million or 30 million patients. I have long held that both are underestimates. From my experience in the clinic and chatting with other eye docs around the country, DED is vastly underdiagnosed. My working number of likely DED sufferers in the U.S. has been 50 million. It has been my contention that dry eye symptoms have been ascribed to other diagnoses by both patients and doctors. While working on a new presentation, I learned that 60 million Americans are diagnosed with allergic conjunctivitis, which confirms my suspicion.

The first patient has been dosed in a phase 3 clinical trial of Dextenza for the treatment of allergic conjunctivitis, Ocular Therapeutix announced in a press release.